human
cytomegaloviru
hcmv
beta
herpesviru
infect
adult
popul
worldwid
infect
mild
even
asymptomat
occur
childhood
primari
infect
follow
lifelong
latenc
persist
mainli
myeloid
lineag
cell
reactiv
hcmv
infect
replic
wide
varieti
cell
type
includ
macrophag
dendrit
cell
epitheli
cell
gland
mucos
tissu
smooth
muscl
cell
fibroblast
hepatocyt
vascular
endotheli
cell
henc
bodili
fluid
organ
transmit
viru
hcmv
consid
pathogen
healthi
individu
normal
immun
system
viru
caus
lifethreaten
diseas
immunocompromis
patient
organ
stem
cell
transplant
patient
aid
patient
inde
although
ganciclovir
avail
treatment
prevent
hcmv
infect
almost
three
decad
viru
still
caus
concern
morbid
mortal
stem
cell
organ
transplant
patient
aid
patient
also
import
human
pathogen
caus
congenit
infect
consider
risk
birth
defect
emerg
evid
also
suggest
hcmv
highli
preval
breast
colon
prostat
cancer
rhabdomyosarcoma
hepatocellular
cancer
salivari
gland
tumor
neuroblastoma
brain
tumor
medulloblastoma
glioblastoma
viru
consid
oncogen
per
se
rather
promot
oncomodulatori
function
lead
aggress
cancer
phenotyp
may
therebi
promot
tumor
progress
scenario
control
hcmv
infect
may
affect
patient
prognosi
support
statement
antivir
treatment
patient
hcmv
posit
glioblastoma
tumor
indic
highli
improv
patient
surviv
rate
hcmv
largest
member
herpesviru
famili
consist
linear
doublestrand
dna
genom
kb
encod
protein
protein
believ
essenti
viru
replic
product
new
viral
progeni
instead
vast
major
protein
aid
viru
interfer
cellular
immunolog
function
enabl
coexist
host
hcmv
also
util
multipl
strategi
exploit
host
function
effici
viru
product
spread
surviv
mani
believ
confer
oncomodulatori
function
viru
life
cycl
initi
entri
cell
first
gene
express
immedi
earli
ie
gene
produc
ie
protein
serv
regulatori
protein
act
transcript
factor
control
viral
earli
late
gene
express
well
host
gene
express
hcmv
known
util
rna
polymeras
ii
pol
ii
transcrib
viral
gene
accur
ie
gene
express
requir
specif
phosphoryl
rna
pol
ii
ctd
carboxyltermin
domain
earli
infect
role
two
polymeras
pol
pol
iii
hcmv
infect
unknown
mani
virus
includ
hcmv
specif
target
nucleolu
facilit
viral
transcript
translat
nucleolu
membran
less
nuclear
organel
assembl
ribosom
subunit
eukaryot
cell
ribosom
assembl
process
trigger
activ
rna
polymeras
pol
mediat
transcript
regul
cell
cycledepend
manner
mammalian
cell
mammalian
cell
contain
sever
hundr
copi
tandemli
repeat
rrna
gene
rdna
transcrib
nucleoli
high
effici
meet
cell
demand
ribosom
protein
synthesi
pol
transcript
machineri
consist
three
main
compon
pol
enzym
tbp
tatabind
protein
taf
tbpassoci
factor
complex
select
factor
tifib
transcript
initi
factorib
transactiv
protein
ubf
upstream
bind
factor
review
tumorigenesi
tightli
regul
relationship
extracellular
signal
ribosom
biosynthesi
disrupt
cancer
cell
begin
excess
product
ribosom
necessari
protein
synthesi
associ
uncontrol
cancer
growth
rrna
major
compon
ribosom
carcinogenesi
requir
increas
synthesi
cmv
protein
local
nucleoli
earli
infect
coloc
nucleolar
protein
fibrillarin
directli
interact
nucleolin
propos
hcmv
induc
rrna
synthesi
ubf
transcript
nucleoli
enlarg
infect
cell
chang
morpholog
upon
specif
inhibit
rrna
synthesi
exit
nucleolu
result
strong
inhibit
hcmv
infect
hcmv
also
impact
function
rb
myc
would
predict
interact
pol
machineri
howev
despit
intrigu
link
effect
hcmv
rrna
transcript
viru
potenti
abil
util
pol
transcript
remain
investig
primari
goal
present
studi
examin
pol
inhibit
affect
transcript
hcmv
gene
andor
viru
product
parallel
rel
contribut
rna
pol
ii
pol
iii
hcmv
earli
gene
transcript
assess
impact
pol
interfer
human
cell
infect
herp
simplex
mous
cell
infect
murin
cytomegaloviru
mcmv
pol
inhibit
success
achiev
two
way
use
sirna
pol
treat
cell
specif
pol
inhibitor
compound
clinic
trial
oncolog
low
dose
actinomycin
actd
result
obtain
experi
present
follow
discuss
potenti
biolog
signific
find
viral
replic
patho
biolog
relat
variou
cell
type
assess
potenti
effect
pol
inhibit
hcmv
replic
fibroblast
pretreat
specif
pol
inhibitor
actd
control
inhibit
pol
activ
anticmv
compound
gcv
left
untreat
cell
thereaft
infect
hcmv
moi
hour
post
infect
hpi
cell
collect
stain
ie
protein
found
ie
protein
express
significantli
lower
cell
reduc
pol
activ
figur
strongest
inhibit
ie
protein
express
observ
actd
treat
cell
nm
reduc
protein
express
also
observ
wb
analysi
well
gcv
treat
cell
figur
howev
protein
express
affect
time
point
treatment
actd
treatment
reduc
cmv
ie
protein
express
level
assess
wb
analysi
time
point
figur
actd
treat
cell
exhibit
strongli
reduc
ubf
stain
mild
effect
ubf
stain
observ
treat
cell
figur
impli
compound
differ
effect
rrna
product
nucleolu
confirm
actd
treatment
reduc
pol
transcript
next
assess
express
pol
transcript
actd
treatment
significantli
decreas
transcript
hcmv
infect
cell
figur
treat
cell
ie
transcript
also
significantli
reduc
figur
treat
cell
exhibit
significantli
reduc
transcript
level
affect
actd
figur
time
point
pol
inhibit
effect
ie
transcript
level
also
significantli
reduc
transcript
level
hcmv
ie
gb
transcript
level
figur
actd
howev
reduc
ie
transcript
affect
gb
transcript
time
point
transcript
level
significantli
reduc
actd
treat
cell
confirm
inhibitori
effect
rrna
product
examin
incorpor
nucleolu
brdu
specif
antibodi
noninfect
infect
cell
fibrillarin
use
nucleolar
marker
found
well
control
actd
strongli
reduc
incorpor
nucleolu
figur
suggest
inhibit
rrna
product
although
known
specif
inhibit
pol
function
drug
may
target
effect
could
affect
hcmv
transcript
well
recent
suggest
induc
cell
cycl
checkpoint
mediat
atmatr
signal
absenc
dna
damag
assess
specif
role
pol
earli
transcript
ie
gene
util
sirna
reduc
pol
function
sirna
pol
significantli
reduc
transcript
level
hour
post
treatment
infect
hour
figur
could
explain
recent
observ
knock
pol
greater
hour
sirna
transfect
reduc
rrna
precursor
level
compar
control
hour
hour
transfect
respect
transcript
level
low
ie
transcript
level
also
significantli
reduc
figur
sirna
pol
reduc
ie
protein
level
alreadi
maintain
significantli
lower
level
ie
protein
express
figur
wb
analys
observ
significantli
reduc
ie
protein
level
sirna
pol
figur
effect
sirna
pol
protein
level
wb
figur
sirna
pol
iii
affect
protein
level
either
time
point
figur
result
unexpect
demonstr
pol
ii
main
rna
polymeras
hcmv
ie
transcript
known
inhibit
rna
pol
ii
iii
without
affect
pol
activ
concentr
polii
highli
sensit
poliii
sensit
assess
contribut
pol
ii
pol
iii
activ
earli
transcript
hcmv
fibroblast
treat
low
high
concentr
without
combin
infect
hcmv
cell
collect
hcmv
ie
transcript
level
analys
taqman
pcr
found
low
high
concentr
almost
complet
block
ie
transcript
supplementari
figur
experi
treatment
trend
reduc
ie
transcript
level
time
point
effect
statist
signific
supplementari
figur
low
concentr
also
reduc
ie
protein
level
wb
presenc
absenc
supplementari
figur
treatment
affect
ie
protein
express
wb
expect
pol
ii
act
time
point
supplementari
figur
well
known
pol
activ
fluctuat
cell
cycl
suspect
variabl
effect
observ
present
experi
may
depend
stage
cell
cycl
transit
address
possibl
perform
new
set
experi
cell
synchron
serum
starvat
releas
cell
cycl
addit
serumcontain
medium
found
condit
treatment
significantli
inhibit
ie
transcript
level
time
point
investig
figur
less
pronounc
hour
post
infect
analys
cell
cycl
statu
indic
time
point
major
differ
treat
nontreat
cell
cell
observ
shift
cell
hour
treat
noninfect
cell
mean
phase
nonsynchronisednontreateduninfect
cell
versu
treatednoninfectednonsynchronis
cell
supplementari
figur
observ
extend
publish
data
abil
arrest
cell
phase
synchronis
cell
observ
distinct
pattern
drug
drive
cell
phase
versu
infect
cell
observ
cell
trend
phase
treat
treat
cell
compar
observ
trend
increas
proport
cell
phase
infectedsynchronis
treat
cell
observ
suggest
infect
delay
mediat
accumul
cell
phase
see
comparison
treatednoninfect
cxtreat
hcmv
infect
cell
taken
togeth
result
impli
hcmv
engag
pol
transcript
certain
phase
cell
cycl
phenomenon
deserv
studi
hcmv
infect
proce
differ
set
hcmv
protein
express
profil
fibroblast
versu
endotheli
cell
therefor
next
assess
whether
pol
inhibit
also
reduc
hcmv
transcript
level
protein
express
human
umbil
cord
endotheli
cell
huvec
observ
treatment
affect
ie
protein
figur
right
panel
transcript
level
figur
hcmv
infect
huvec
reduct
figur
left
panel
howev
wb
observ
reduc
protein
level
figur
analys
transcript
level
found
reduc
hour
figur
thu
appear
differ
effect
hcmv
transcript
endotheli
cell
fibroblast
result
experi
util
confirm
previou
observ
demonstr
pol
ii
main
polymeras
util
hcmv
produc
mrna
howev
also
found
pol
engag
ie
transcript
occur
appear
depend
cell
cycl
assess
whether
reduc
level
ie
transcript
ie
protein
product
mediat
compromis
pol
function
also
affect
viru
product
assess
product
extracellular
viru
gcv
treat
hcmv
infect
cell
moi
viru
contain
supernat
collect
hcmv
infect
fibroblast
treat
gcv
dpi
transfer
new
fibroblast
cultur
assess
three
day
later
hcmv
ie
posit
cell
measur
viabl
viru
supernat
treatment
result
reduc
viru
product
dpi
figur
expect
gcv
complet
block
viru
product
dpi
figur
observ
suggest
pol
ii
later
fulli
compens
pol
iirel
ie
transcript
inhibit
earli
phase
infect
term
result
product
viru
found
strike
effect
pol
inhibit
hcmv
transcript
level
fibroblast
earli
time
infect
assess
whether
util
pol
earli
transcript
uniqu
hcmv
also
involv
transcript
herp
virus
infect
treat
cell
found
treatment
significantli
reduc
level
ie
transcript
even
observ
significantli
reduc
transcript
level
figur
analyz
protein
level
protein
detect
wb
hour
post
infect
treat
cell
differ
compar
nontreat
cell
figur
immunofluoresc
stain
treat
infect
cell
show
effect
figur
actd
inhibit
pol
activ
treatment
significantli
reduc
number
posit
cell
figur
gcv
treatment
use
control
also
complet
inhibit
infect
time
point
figur
assess
whether
pol
also
util
mcmv
infect
earli
transcript
phase
treat
mcmv
infect
cell
observ
differ
transcript
level
versu
nontreat
cell
figur
also
observ
differ
number
posit
cell
total
ie
protein
level
immunofluoresc
stain
wb
figur
gcv
reduc
number
mcmv
posit
cell
well
total
protein
level
figur
although
observ
differ
transcript
level
figur
untreat
versu
gcv
treat
cell
thu
pol
inhibit
effect
mcmv
ie
transcript
protein
product
replic
hcmv
strictli
control
viru
util
host
cell
factor
surviv
earlier
studi
demonstr
hcmv
util
rna
pol
ii
transcrib
viral
gene
produc
viral
mrna
previou
studi
also
shown
hcmv
specif
target
nucleolu
facilit
viral
transcript
translat
mechan
well
understood
pol
specif
activ
polymeras
nucleolu
inhibit
rrna
synthesi
result
exit
hcmv
nucleolu
strong
inhibit
hcmv
infect
hypothes
pol
may
play
role
earli
viral
transcript
consist
hypothesi
found
deplet
pol
sirna
chemic
inhibit
pol
result
significantli
decreas
ie
mrna
protein
level
human
fibroblast
notabl
effect
celltyp
depend
analog
inhibit
pol
alter
transcript
earli
hcmv
gene
human
endotheli
cell
furthermor
reduc
ie
transcript
protein
product
seen
fibroblast
upon
pol
inhibit
appear
cell
cycl
depend
reduc
ie
protein
level
observ
upon
pol
inhibit
earli
phase
infect
delay
viru
product
compens
later
stage
hcmv
replic
cycl
significantli
affect
viru
product
fibroblast
examin
day
post
infect
analog
scenario
seen
fibroblast
infect
hcmv
pol
inhibit
also
reduc
transcript
anoth
herp
viru
human
fibroblast
contrast
inhibit
pol
fail
affect
mcmv
transcript
test
murin
fibroblast
taken
togeth
observ
suggest
util
pol
hcmv
cell
type
depend
pol
ii
produc
viral
mrna
viru
replic
pol
inhibit
affect
viru
product
later
time
infect
specul
hcmv
would
util
pol
earli
transcript
phase
demonstr
pol
inhibit
result
significantli
reduc
ie
transcript
level
ie
protein
product
hcmv
infect
cell
pol
transcript
ribosom
rrna
gene
confin
nucleolu
protein
nucleolu
dedic
rrna
transcript
bioinformat
analys
nucleolar
proteom
suggest
mani
nucleolar
resid
protein
also
affect
mrna
matur
chromatin
structur
cell
cycl
control
dna
replic
repair
mechan
nucleolu
may
also
regul
activ
tumor
suppressor
protooncogen
sinc
transcript
activ
rrna
rate
limit
cell
high
demand
rapid
growth
prolifer
surpris
pol
machineri
target
mani
virus
includ
hcmv
exploit
effici
transcript
benefit
nucleolu
play
import
role
replic
dna
rna
virus
also
exploit
virus
take
control
cell
cycl
viral
perspect
role
nucleolu
cell
cycl
control
ribosom
biogenesi
special
interest
hcmv
hcmv
protein
rapidli
localis
nucleolu
viru
entri
deliv
viru
particl
propos
play
import
role
earli
event
hcmv
transcript
develop
lytic
infect
phase
rrna
synthesi
ribosom
assembl
increas
meet
demand
synthesi
phase
protein
regul
nucleolar
protein
phosphoryl
transcript
factor
interact
pol
kinas
activ
may
abl
phosphoryl
nucleolar
protein
facilit
process
nucleolar
accumul
promin
low
phase
cell
cycl
hcmv
need
arrest
phase
replic
initi
incom
may
play
role
initi
process
viru
may
exploit
pol
pol
ii
differ
differ
cell
type
particularli
cell
hcmv
establish
latenc
pol
ii
apart
use
product
host
viral
mrna
highli
activ
phase
expect
regul
express
host
possibl
viral
mirna
hcmv
encod
mirna
regul
ie
express
interact
rna
reduc
ie
protein
product
prematur
express
shown
decreas
hcmv
replic
express
also
known
reduc
late
time
infect
mediat
highli
accumul
late
infect
induc
overexpress
acut
infect
also
result
reduc
product
viru
thu
may
essenti
hcmv
decreas
express
maintain
high
replic
rate
howev
role
may
differ
cell
viru
establish
latenc
hcmv
establish
latenc
myeloid
lineag
cell
hcmv
enter
cell
may
util
pol
phase
produc
protein
hcmv
known
induc
arrest
necessari
initi
dna
replic
may
explain
high
util
pol
ii
viral
mrna
product
pol
ii
highli
activ
phase
pol
ii
produc
inhibit
protein
translat
result
reduc
mediat
activ
late
gene
transcript
expect
facilit
establish
latenc
rather
promot
activ
viru
replic
futur
studi
address
aspect
would
highli
interest
understand
molecular
mechan
regul
establish
hcmv
latenc
found
inhibit
protein
express
effect
treatment
appear
pronounc
cell
phase
supplementari
figur
reduct
ie
protein
express
earli
phase
infect
delay
necessari
later
viru
replic
viru
product
reduc
dpi
henc
possibl
hcmv
rapidli
replic
exploit
pol
make
ie
transcript
speed
replic
earli
time
post
infect
fibroblast
hour
treatment
shown
arrest
cell
phase
often
result
accumul
mediat
cell
cycl
arrest
senesc
apoptosi
depend
statu
cell
properti
use
anticanc
effect
current
evalu
clinic
trial
observ
variabl
result
inhibit
ie
transcript
cell
cycl
depend
treatment
initi
cell
cycl
may
differ
effect
outcom
hcmv
transcript
treatment
involv
effect
downstream
apoptosi
cell
cycl
arrest
senesc
possibl
compound
arrest
cell
phase
also
neg
influenc
hcmv
replic
also
possibl
effect
observ
pol
inhibit
hcmv
transcript
affect
effect
factor
interact
pol
machineri
ie
rb
myc
therebi
pol
could
act
indirectli
inhibit
hcmv
transcript
howev
sinc
similar
result
reduc
ie
transcript
protein
product
obtain
follow
pol
knockdown
use
sirna
favor
viral
mechan
involv
pol
directli
nevertheless
result
demonstr
inhibit
pol
affect
hcmv
transcript
pol
inhibitor
present
evalu
clinic
oncolog
trial
whether
pol
inhibit
would
use
antivir
strategi
cmv
posit
cancer
form
interest
evalu
viru
replic
well
cancer
cell
express
ie
protein
effect
pol
inhibit
product
hcmv
ie
transcript
protein
differ
fibroblast
versu
endotheli
cell
context
interest
note
replic
hcmv
faster
fibroblast
endotheli
cell
hcmv
entri
pathway
differ
two
cell
type
hcmv
enter
fibroblast
fusion
plasma
membran
hcmv
infect
endotheli
cell
via
receptormedi
endocytosi
review
differ
cellular
receptor
engag
may
also
affect
downstream
signal
cascad
product
ie
protein
delay
endotheli
cell
engag
pol
hcmv
fibroblast
endotheli
cell
may
therefor
also
depend
differ
cellular
activ
pathway
induc
viru
host
cell
interact
differ
cell
type
summari
found
inhibit
pol
neg
affect
hcmv
transcript
product
ie
protein
fibroblast
endotheli
cell
engag
pol
earli
phase
viru
infect
could
benefit
speed
replic
certain
cell
type
human
fetal
lung
fibroblast
purchas
atcc
umbil
vein
cell
huvec
either
freshli
isol
donor
purchas
clonet
lonza
respect
grown
minimum
essenti
medium
mem
invitrogen
supplement
glutamin
fetal
bovin
serum
fb
standard
penicillin
streptomycin
ps
huvec
cultur
endotheli
basal
medium
supplement
singl
quot
clonet
lonza
mous
embryon
fibroblast
cell
purchas
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fetal
bovin
serum
fb
standard
penicillin
streptomycin
ps
mycoalert
mycoplasma
detect
kit
clonet
lonza
use
verifi
cell
mycoplasmafre
hcmv
clinic
strain
kind
gift
dr
giusepp
gerna
univers
pavia
itali
kind
offer
prof
maria
masucci
lab
karolinska
institut
sweden
mcmv
smith
strain
kindli
provid
dr
frank
stassen
univers
maastricht
netherland
use
studi
viru
propag
huvec
titrat
fibroblast
atcc
frozen
cell
pretreat
either
medchem
express
actinomycin
sigma
aldrich
ganciclovir
hoffman
la
roch
ltd
left
untreat
infect
hcmv
strain
mcmv
smith
strain
drug
present
medium
whole
experi
synchron
experi
cell
confluenc
starv
lowserum
fb
cultur
medium
time
cell
cultur
confluenc
nonsynchron
avoid
cellcel
contact
synchron
behaviour
order
control
grow
cell
earlier
note
cell
confluenc
exhibit
cell
cycl
profil
synchron
synchron
nonsynchron
cell
plate
approxim
confluenc
medium
fb
next
day
plate
treat
h
thereaft
infect
hcmv
strain
noninfect
infect
nontreat
treat
cell
collect
post
infect
ie
transcript
analysi
dna
content
analysi
cell
trypsin
collect
plate
centrifug
min
room
temperatur
pellet
resuspend
pb
thereaft
ethanol
ad
fix
cell
cell
kept
ice
ethanol
suspend
cell
centrifug
min
g
room
temperatur
pellet
resuspend
dapi
stain
solut
cell
fluoresc
measur
flow
cytomet
analysi
done
summit
softwar
cellular
rna
isol
rneasi
mini
kit
qiagen
hour
post
infect
hpi
revers
transcrib
cdna
superscript
iii
firststrand
kit
invitrogen
life
technolog
realtim
pcr
perform
use
hcmv
custom
made
taqman
assay
appli
biosystem
detect
hcmv
immedi
earli
ie
gb
mcmv
immedi
earli
primer
design
accord
taqman
fast
univers
master
mix
power
sybr
green
master
mix
appli
biosystem
use
reaction
power
sybr
green
master
mix
perform
detect
rrna
transcript
also
transcript
design
accord
human
assay
id
use
housekeep
gene
normal
taqman
assay
perform
use
fast
realtim
pcr
system
appli
biosystem
total
cycl
final
volum
per
reaction
result
analyz
sd
softwar
method
use
quantifi
rel
express
sirna
studi
stealth
sirna
thermofish
scientif
invitrogen
lipofectamin
rnaimax
protocol
invitrogen
follow
manufactur
instruct
use
allstar
neg
control
sirna
qiagen
serv
neg
control
brief
cell
confluenc
plate
transfect
sirna
infect
hcmv
moi
cell
harvest
quantit
taqman
pcr
analysi
furd
base
incorpor
fluorineconjug
uridin
analogu
reflect
rrna
compris
cellular
rna
cell
incub
mm
furd
sigmaaldrich
cat
dmem
incub
allow
min
stop
medium
remov
cell
wash
cold
pb
detect
incorpor
furd
cell
fix
formaldehyd
solut
pb
room
temperatur
permeabil
triton
solut
pb
incub
monoclon
antibrdu
antibodi
clone
sigma
aldrich
cat
actinomycin
use
control
drug
cell
seed
cultur
slide
infect
hcmv
strain
mcmv
moi
slide
fix
pfa
minut
wash
three
time
pb
incub
fc
receptor
blocker
innovex
bioscienc
cat
block
use
dako
protein
block
dako
cytom
cat
thereaft
slide
stain
monoclon
mous
antihcmv
ie
merckmillipor
cat
monoclon
mous
virusi
corpor
cat
novocastra
cat
mous
mcmv
croma
ab
rabbit
polyclon
ubf
upstream
bind
factor
santa
cruz
biotechnolog
cat
immunoreact
reveal
ad
secondari
antibodi
conjug
alexa
fluor
analyz
zeiss
confoc
microscop
lsm
briefli
cell
lyse
ripa
buffer
supplement
proteas
inhibitor
concentr
protein
measur
use
pierc
tm
bca
protein
assay
kit
sampl
boil
laemmli
buffer
minut
wb
assay
perform
precast
gel
biorad
sampl
transfer
onto
pvdf
membran
membran
stain
use
primari
antibodi
mous
polyclon
santa
cruz
biotechnolog
cat
rabbit
polyclon
vinculin
abcam
cat
antibodi
mous
antihcmv
ie
merckmillipor
cat
mous
antihcmv
novocastra
cat
mous
monoclon
virusi
corpor
cat
mous
monoclon
mcmv
croma
ab
secondari
antibodi
conjug
irdy
goat
antirabbit
irdy
cat
pn
goat
antimous
irdy
cat
pn
licor
develop
use
odyssey
clx
licor
quantif
band
densiti
perform
imag
studio
lite
programm
grown
triplic
cultur
plate
approxim
confluenc
pretreat
either
gcv
subsequ
infect
hcmv
left
uninfect
cell
wash
dpi
retreat
correspond
drug
supernat
collect
dpi
store
determin
infecti
viru
supernat
seed
cultur
slide
infect
supernat
slide
fix
dpi
immunofluoresc
stain
ie
see
data
analys
twotail
test
use
prism
version
graphpad
inc
data
mean
sem
experi
pvalu
denot
follow
p
p
p
p
